This site is intended for U.S. healthcare professionals only.

About KENGREAL® (cangrelor)

Pathophysiology—Thrombosis after injury

Thrombotic response to laser-induced injury in mouse cremaster muscle arteriole performed in vitro.1-3

Information featured here includes in vitro data, the clinical significance of which has not been established.

Platelet inhibition

KENGREAL® is the first and only IV inhibitor that blocks platelet ADP activation and aggregation.1

Blood levels of KENGREAL (cangrelor) and platelet activity with a 30 mcg/kg IV bolus followed by a 4 mcg/kg/min IV infusion.

Phase 1 study in healthy volunteers (n=10); dose: 30 μg/kg IV bolus + 4 μg/kg/min IV infusion.

Blood levels of KENGREAL® (green line/PK) and platelet activity (blue line/PD) were assessed over 6 minutes by whole blood impedance aggregometry in response to 20 μM of adenosine diphosphate (ADP).4

After administration of a 30 mcg/kg IV bolus followed by a 4 mcg/kg/min IV infusion, platelet inhibition occurs within 2 minutes. The figure above shows the effect on platelet activity, and its relation to KENGREAL® plasma concentration, of administering a 30 mcg/kg IV bolus, followed by a 1-hour 4 mcg/kg/min IV infusion of KENGREAL®. The antiplatelet effect is maintained for the duration of the infusion. After discontinuation of the infusion, the antiplatelet effect decreases rapidly and platelet function returns to normal within 1 hour.4

Pharmacology*

Developed for acute use in PCI

KENGREAL® (cangrelor)1
Compound class ATP analogue
IV administration YES
Direct-acting, does not require metabolism YES
Onset of PD effect ~2 min
Reversible P2Y12 receptor binding YES
Half-life 3–6 min
Offset of PD effect ~1 h
Clearance of active substance Independent of organ function; esterases

KENGREAL® administered intravenously has linear pharmacokinetics in both healthy volunteers and patients. KENGREAL® is rapidly distributed and metabolized, reaching Cmax within 2 minutes after administration of an intravenous bolus followed by infusion.

*The correlation of pharmacology or chemical class with clinical efficacy or safety results has not been established.

KENGREAL® is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

ATP=adenosine triphosphate.

References: 1. KENGREAL® (cangrelor) Prescribing Information. 2016. 2. Gachet C. J Thromb Haemost. 2015;13:S313-S322. 3. Stalker T, et al. Blood. 2013;121:1875-1885. 4. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Clin Pharmacol. 2010;50:27-35.

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Please see full prescribing information.

www.kengreal.com

This site is intended for U.S. healthcare professionals. If you are a U.S. healthcare professional, click OK to continue.

Cancel
Ok